These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22237669)

  • 21. A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination.
    Patel CK; Walker NJ; Kam JK
    Br J Ophthalmol; 2010 Aug; 94(8):1107-9. PubMed ID: 20558426
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
    Dorta P; Kychenthal A
    Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series.
    Dani C; Frosini S; Fortunato P; Bertini G; Pratesi S; Pollazzi L; Caputo R; La Torre A
    J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2194-7. PubMed ID: 22506618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.
    Lalwani GA; Berrocal AM; Murray TG; Buch M; Cardone S; Hess D; Johnson RA; Puliafito CA
    Retina; 2008 Mar; 28(3 Suppl):S13-8. PubMed ID: 18317338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
    Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
    Azad R; Chandra P
    Indian J Ophthalmol; 2007; 55(4):319; author reply 320. PubMed ID: 17595491
    [No Abstract]   [Full Text] [Related]  

  • 28. Bevacizumab for retinopathy of prematurity.
    Good WV; Palmer EA
    N Engl J Med; 2011 Jun; 364(24):2359; author reply 2361-2. PubMed ID: 21675899
    [No Abstract]   [Full Text] [Related]  

  • 29. Intravitreous bevacizumab adult safety data: the evidence so far.
    Al-Qureshi S; Shaikh S
    Clin Exp Ophthalmol; 2012; 40(1):3-5. PubMed ID: 22304024
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
    O'Keefe M
    Ir Med J; 2011; 104(7):197. PubMed ID: 21957683
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
    Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
    Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [VEGF antibodies as therapy for retinopathy of prematurity].
    Oberacher-Velten IM; Helbig H
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab for retinopathy of prematurity.
    Reynolds JD
    N Engl J Med; 2011 Feb; 364(7):677-8. PubMed ID: 21323546
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 36. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
    Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
    Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.
    Quiroz-Mercado H; Ustariz-González O; Martinez-Castellanos MA; Covarrubias P; Dominguez F; Sanchez-Huerta V
    Semin Ophthalmol; 2007; 22(2):109-25. PubMed ID: 17564934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Mintz-Hittner HA; Kuffel RR
    Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.
    Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA
    Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does Bevacizumab Alter Vascularization Potential in Retinopathy of Prematurity?
    Isaac M; Mireskandari K; Tehrani N
    Ophthalmology; 2016 Sep; 123(9):2042-3. PubMed ID: 27320519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.